Literature DB >> 20517339

Hematology. Individualized methotrexate dosing in primary CNS lymphoma.

Lauren E Abrey1.   

Abstract

Although high-dose methotrexate is widely accepted as the most effective chemotherapeutic agent for primary cns lymphoma, no optimal dose or dosing strategy has been established. Researchers from the International Extranodal Lymphoma Study Group used clinical trial data to explore whether or not an area under the curve model might be useful to optimize methotrexate dosing. The results strongly suggest that effective methotrexate dose is an important variable in patient outcome.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20517339     DOI： 10.1038/nrclinonc.2010.66

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.

Authors:  G Vassal; D Valteau; M Bonnay; C Patte; F Aubier; J Lemerle
Journal:  Pediatr Hematol Oncol       Date:  1990       Impact factor: 1.969

2.  Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.

Authors:  S Hiraga; N Arita; T Ohnishi; E Kohmura; K Yamamoto; Y Oku; T Taki; M Sato; K Aozasa; T Yoshimine
Journal:  J Neurosurg       Date:  1999-08       Impact factor: 5.115

3.  Methotrexate levels and outcome in osteosarcoma.

Authors:  Shayna Zelcer; Michael Kellick; Leonard H Wexler; Weiji Shi; Marie Sankaran; Sarah Lo; John Healey; Andrew G Huvos; Paul A Meyers; Richard Gorlick
Journal:  Pediatr Blood Cancer       Date:  2005-06-15       Impact factor: 3.167

Review 4.  Therapeutic challenges in primary CNS lymphoma.

Authors:  Patrick G Morris; Lauren E Abrey
Journal:  Lancet Neurol       Date:  2009-06       Impact factor: 44.182

5.  Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Authors:  M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

6.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Authors:  Andrés J M Ferreri; Michele Reni; Marco Foppoli; Maurizio Martelli; Gerasimus A Pangalis; Maurizio Frezzato; Maria Giuseppina Cabras; Alberto Fabbri; Gaetano Corazzelli; Fiorella Ilariucci; Giuseppe Rossi; Riccardo Soffietti; Caterina Stelitano; Daniele Vallisa; Francesco Zaja; Lucía Zoppegno; Gian Marco Aondio; Giuseppe Avvisati; Monica Balzarotti; Alba A Brandes; José Fajardo; Henry Gomez; Attilio Guarini; Graziella Pinotti; Luigi Rigacci; Catrina Uhlmann; Piero Picozzi; Paolo Vezzulli; Maurilio Ponzoni; Emanuele Zucca; Federico Caligaris-Cappio; Franco Cavalli
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

7.  Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.

Authors:  A J M Ferreri; E Guerra; M Regazzi; F Pasini; A Ambrosetti; A Pivnik; A Gubkin; A Calderoni; M Spina; A Brandes; F Ferrarese; A Rognone; S Govi; S Dell'Oro; M Locatelli; E Villa; M Reni
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
  7 in total
  2 in total

1.  Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Authors:  Markus Joerger; Andrés J M Ferreri; Stephan Krähenbühl; Jan H M Schellens; Thomas Cerny; Emanuele Zucca; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  A minimal physiologically based pharmacokinetic model for high-dose methotrexate.

Authors:  Giuseppe Pesenti; Marco Foppoli; Davide Manca
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-13       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.